While our focus on service and solutions sets us apart, R&D is at our core. In 2000, our co-founder, Dr. Laurie Stephen, helped introduce the first 5-plex commercial human cytokine kits for the Luminex platform. That innovative drive continued at Ampersand’s precursor company, Multiplex Biosciences—later Myriad RBM—which launched close to 100 new assays in its nine years of existence.
Myriad RBM’s New York site grew from four employees to 22 before spinning off its parent in 2015, becoming Ampersand Biosciences. In addition to developing xMAP-based research use kits and assays, we design and execute biomarker tests for mouse, rat, hamster, ferret, canine and human samples. We launched these testing services to assist small teams unfamiliar with the complexity of performing multiplex immunoassays—saving clients both time and money. And for researchers working with limited sample quantities, our technology to miniaturize custom assays requires smaller sample sizes than other off-the-shelf kits.